Results 101 to 110 of about 32,386 (229)

Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature

open access: yesBiologics: Targets & Therapy, 2009
Jochen Schmitt, Gottfried WozelDepartment of Dermatology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, GermanyAbstract: Psoriasis is a chronic inflammatory disease affecting 2% to 3% of the population in Western countries ...
Jochen Schmitt, Gottfried Wozel
doaj  

Molecular Changes Induced by Carbon Dioxide Laser in Hailey‐Hailey Disease: A Potential Mechanism Underlying Treatment Efficacy

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Introduction Hailey‐Hailey disease (HHD) is a rare genodermatosis caused by mutations in the ATP2C1 gene that codes for SPCA1, a calcium transporter in the epidermis. HHD impairs quality of life, and no curative treatment exists. Methods To confirm the efficacy and safety of CO2 laser in HHD, we conducted a randomized, prospective, controlled ...
Javier Antoñanzas   +7 more
wiley   +1 more source

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Data from 2731 patients with hidradenitis suppurativa (HS) treated with biologics for 12–16 weeks in phase III randomized controlled trials (RCT) were included in a network meta‐analysis (NMA). Adalimumab showed the highest efficacy in achieving a clinical HS response 50 (HiSCR50) and the lowest incidence of adverse events (AE).
Laura Calabrese   +4 more
wiley   +1 more source

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Forty‐three HS specialists from 22 European countries reported adherence to HS guidelines and use of antibiotics before biologics despite limited efficacy and rapid relapse (49% within 1–3 months). Seventy‐nine per cent supported short‐term biologics for severe Hurley I disease.
Georgios Nikolakis   +41 more
wiley   +1 more source

Hair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Hair follicles (HFs) were extracted from skin biopsies. From these, original sequencing data were obtained and integrated with two independent studies to build a HF single‐cell transcriptomic atlas. It enabled delineating the fate of HF stem cells.
Audrey Onfroy   +17 more
wiley   +1 more source

Bimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer   +3 more
wiley   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui   +15 more
wiley   +1 more source

Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology. [PDF]

open access: yesArthritis Res Ther
Burlo F   +8 more
europepmc   +1 more source

Severe and disseminated atypical mycobacteriosis of the skin under immunosuppression

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Veronika Zenderowski   +6 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault   +51 more
wiley   +1 more source

Home - About - Disclaimer - Privacy